Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced dis

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease. Martin McMahon, PhD, senior director of preclinical translation at Huntsman Cancer Institute and professor of dermatology at the U, evaluated an investigative compound of the drug daraxonrasib in NRAS-driven melanoma. NRAS-driven melanoma is an aggressive type of skin cancer driven by mutations in the NRAS gene. Daraxonrasib, developed by Revolution Medicines, targets and inhibits RAS, a protein that drives cancer when altered. NRAS is a subtype of RAS that is mutated in roughly a quarter of melanoma cases. The results of daraxonrasib as a treatment for metastatic pancreatic cancer-in which it doubled patients' life expectancy in a Phase 3 clinical trial-recently received a standing ovation from thousands of physicians at the American Society of Clinical Oncology Annual Meeting. Huntsman Cancer Institute was one of just 60 hospitals worldwide who offered that trial (RASolute 302).

The remarkable success of daraxonrasib in the treatment of pancreatic cancer indicates that we are in an era where even the most recalcitrant RAS-driven cancers can be treated. Our data strongly supports the potential future clinical utility of treating patients with NRAS-driven melanoma with daraxonrasib." Martin McMahon, PhD, senior director of preclinical translation, Huntsman Cancer Institute and professor of dermatology, University of Utah

McMahon and his team evaluated the effectiveness of the RAS inhibitor in numerous preclinical models, including melanoma samples from patients. The results of the study have been published in Cancer Research, a journal of the American Association for Cancer Research. "All our NRAS-driven models were very responsive to this RAS inhibitor. It's actually quite rare that we see shrinkage of NRAS-driven tumors," says Mona Foth, PhD, research scientist at Huntsman Cancer Institute and first author of the publication. "It's inspiring to think that these results could potentially lead to a new patient therapy that will help them overcome their disease."

Melanoma is the deadliest form of skin cancer, and their research aims to help fulfill an unmet clinical need in patients with metastatic disease. These patients usually receive immunotherapy, the harnessing of a patient's own immune system, as the earliest form of treatment. Immunotherapy has revolutionized metastatic melanoma care. Foth says the treatment is effective in about half of melanoma patients, sometimes with deep and durable responses. If immunotherapy fails or becomes less effective, physicians switch to targeted therapies as a secondary line of treatment. Targeted therapies attack oncoproteins and their effectors to kill cancer cells or slow their growth. "Patients with other mutations like BRAF have access to clinically approved secondary lines of treatment. But patients with NRAS-driven melanoma do not have effective targeted therapies to treat their cancer," says McMahon. "Daraxonrasib is a targeted therapy that may provide another path for treatment and hope for patients affected by this devastating disease." The team also observed that some of the models became resistant to the drug, as often happens in patients taking pathway-targeted therapies. Resistance to daraxonrasib was tied to mutations in the mitogen-activated protein kinase (MEK1), a protein downstream of RAS, or to loss of expression of cyclophilin A, a chaperone protein required for the inhibitory action of daraxonrasib toward RAS proteins. "We will need to do more research to find drug combinations, based on a backbone of daraxonrasib, that will increase the depth and durability of melanoma patient responses," says McMahon. McMahon and Foth hope the drug will move into a clinical trial for patients who are either ineligible for immunotherapy or whose immunotherapy did not work. "This research reflects the power of Huntsman Cancer Institute's integrated approach, where laboratory discovery, translational research, and clinical trials come together to accelerate progress for patients," says Neli Ulrich, PhD, MS, executive director of the Comprehensive Cancer Center and chief scientific officer at Huntsman Cancer Institute, Jon and Karen Huntsman Presidential Professor in Cancer Research, and professor of population health sciences at the U. "We are proud to contribute to advances that have the potential to change treatment options for our patients with melanoma. This is of utmost importance in Utah and the Mountain West, where melanoma is a very common cancer." The critical research happening every day at Huntsman Cancer Institute is supported by the National Institutes of Health/National Cancer Institute, including Cancer Center Support Grant P30 CA042014, as well as Huntsman Cancer Foundation.

Foth, M., et al. (2026). Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS -Mutated Melanoma. Cancer Research. DOI: 10.1158/0008-5472.can-26-1313. https://aacrjournals.org/cancerres/article-abstract/doi/10.1158/0008-5472.CAN-26-1313/785950/Genetic-Drivers-of-Sensitivity-or-Resistance-to

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01What impact do you think the use of AI in drug discovery could ultimately have for patients?

One of the first ways in which this would be really felt by patients is through the repurposing of existing drugs for new diseases. Clearly, even though one could improve the process in a number of ways in terms of speeding up medicinal chemistry programs and potentially speeding up the amount of things such as toxicity trials etc., that is still going to take time. However, if we can take existing drugs, perhaps drugs which have gone off patent or are currently being marketed for another indication, and repurpose them in areas where there are high unmet medical needs, those drugs could go into that new indication in phase 2 in patients and you would know very quickly whether the drug worked or not. Then the route to market or the route to being able to make the drug more broadly available to patients would be much more rapid because you don't have to go through all those earlier stages of toxicity, testing, phase 1 testing, volunteers and so on.

Source: www.news-medical.net ↗
02With graph neural networks, foundation models, and diffusion models transforming the field, what can we predict reliably today that was difficult a decade ago and are there still any blind spots?

One major example is protein structure. Methods such as AlphaFold and Boltz-2 have transformed how we generate 3D structural data. Accurate protein structure prediction has been a decades-old challenge, and while there is still work to do on underrepresented protein classes, these models have opened an extraordinary pathway. We have also seen progress in multi-output models. Just over a decade ago (circa 2013), toxicology and property prediction models often focused on one endpoint at a time. Now, multi-output models, especially from methods such as graph neural networks (GNNs) and other deep learning methods, can predict multiple endpoints simultaneously. This allows for transfer learning between related properties. That creates opportunities across ADMET (absorption, distribution, metabolism, excretion, and toxicity) prediction and toxicology. Another exciting area is machine learning potentials. Molecular simulations traditionally rely on fixed mathematical functions to describe molecular interactions, but neural potentials can now replace or augment those functions. They can, in many cases, provide highly accurate simulations and structures at lower computational cost than quantum chemistry. However, its not just down to model architectures. The biggest blind spot behind all of these advances remains careful data curation, annotation, and collection. Open databases for example ChEMBL, PubChem and Chemspider together with data initiatives such as OpenADEMT and OpenBind to name but a few are making notable progress here. We still see some data for example on formulation chemistry often receiving less attention. Its is not just about data scale, but quality that is critical here to. Accessible high quality data sets are the fuel of AI methods. Architecture matters, but high-quality, accessible and abundant data is also absolutely critical.

Source: www.news-medical.net ↗
03From Spirulina to Seaweed: How are different types of algae integral to human diets?

Algae are photosynthetic aquatic creatures that grow through the consumption of nutrients, light, and carbon dioxide. They are a diverse group of creatures that include tiny single-celled algae and enormous kelp, as well as seaweed 1. Numerous prokaryotic and eukaryotic algae species are desirable food sources for humans due to their inherent qualities 2,3. Human intake of macroalgae such as seaweed and microalgae like phytoplankton dates back many years. Multicellular macroscopic aquatic plants, or macroalgae, are classified into three taxa: Phaeophyceae, or brown algae, Rhodophyta or red algae, and Chlorophyta or green algae. Microalgae, the unicellular counterpart of macroalgae, are categorized in a broader framework that includes prokaryotic cyanobacteria (blue-green algae), Euglenophyta, and Chlorophyta, which are genetically distinct from one another. The ancient populations of Chad and the Aztec culture were already familiar with the cyanobacteria spirulina, which is currently advertised as a superfood in the West 4. In Burma, Vietnam, and India, other cyanobacteria/microalgae, like Spirogyra and Oedogonium, were eaten as food or as a supplement 4. Seaweed is a staple of daily meals in many Asian and Pacific civilizations, including Korea, Japan, and Indonesia, as well as Hawaii and New Zealand 5.

Source: www.news-medical.net ↗
04What supplements really work?

The bulk of vitamins and supplements containing fish oil, biotin, and vitamins A, C, and E can potentially promote nail and hair growth. You can find dietary supplements with higher concentrations of vitamins and minerals that aid skin, hair, and nail health. Fish oil supplements make nails and hair shiny. Fish oil also serves as an agent that can decrease signs of aging. If sun exposure damages the skin, the omega-3 fatty acids in fish oil can help. Biotin, also known as B7, increases hair density and strengthens it. It is found naturally in bananas, eggs, and milk. Vitamins are vital for skin health as well. Vitamin A reduces acne flairs and helps with changes due to aging like wrinkling. A vitamin A deficiency may increase the risk of acne because it becomes difficult for dead skin to slough off hair follicles, blocking pores. Vitamin B lowers the risk of precancerous growths and nonmelanoma skin cancer. Vitamin C is an antioxidant. It leads the fight against free radicals to help stimulate collagen and brighten skin. It also helps to prevent the formation of unneeded melanin that causes uneven skin pigmentation.

Source: www.medicinenet.com ↗
05How does vitamin D strengthen the immune system?

More specifically, the study showed that the female patient produced very few cathelicidins, which is a natural toxin found in the immune cells of the lungs needed to fight tuberculosis. In most people infected by tuberculosis, tuberculosis bacteria attack the immune cells of the lungs. The immune cells fight the bacteria by eating them. But the tuberculosis bacterium has developed various evasive mechanisms that reduce the immune cells’ ability to digest and thus to kill the Mtb. “You could say that the tuberculosis bacterium has developed a way to lull the immune cells to sleep. This enables the disease the hide inside the immune cells, making it invisible to other parts of the immune system,” Martin Kongsbak-Wismann explains. This is where vitamin D enters the picture. Because vitamin D is able to counteract the soporific effect of the tuberculosis bacteria by making the immune cells produce more of the cathelicidin toxin. “Cathelicidin is like a microscopic needle that is able to pierce the tuberculosis bacteria. And when it does, it weakens the bacteria’s soporific effect on the immune cells. This restores the immune cells’ ability to kill tuberculosis bacteria,” says Martin Kongsbak-Wismann and adds: “We were amazed by the effect of vitamin D. In immune cells from healthy control subjects, vitamin D improved the cells’ ability to fight Mtb, whereas in the female patient’s immune cells we saw no response to vitamin D. This shows that vitamin D is key to the immune system’s ability to fight Mtb and prevent tuberculosis.” Al-Jaberi, F.A.H., et al. (2022) Reduced vitamin D-induced cathelicidin production and killing of Mycobacterium tuberculosis in macrophages from a patient with a non-functional vitamin D receptor: A case report. Frontiers in Immunology. doi.org/10.3389/fimmu.2022.1038960.

Source: www.news-medical.net ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →